Moreover, although we had excluded patients who had malignant tumor or severe immunosuppression (such as oral glucocorticoids treatment), concurrent medication (such as proton pump inhibitors or insulin sensitizing agents) or follow-up intervention may have influenced bone mineral density. The gene discussed is INS; the disease is cancer.